GlassScriptPhysician profile
Janice F Eakle
NPI 1386635019
$17,219.33
in general payments reported to CMS, 2019-2025
82 companies · $3,272 in 2025
The $3,272 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,748 · 2020: $1,794 · 2021: $1,856 · 2022: $2,620 · 2023: $2,493 · 2024: $3,437 · 2025: $3,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,153 · Education: $48.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,152.85 |
| Education | $48.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,094.47 | 2019-2025 | Piqray, Kisqali |
| Celgene Corporation | $1,091.67 | 2020-2025 | Reblozyl, Opdualag, Pomalyst |
| Pfizer INC. | $1,061.83 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,034.16 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $1,020.40 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $828.26 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $770.94 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $678.06 | 2019-2025 | Venclexta |
| Beigene USA, INC. | $599.78 | 2020-2025 | Brukinsa |
| Incyte Corporation | $555.47 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $490.70 | 2020-2025 | Calquence, Imfinzi |
| Gilead Sciences, INC. | $489.67 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $465.86 | 2019-2025 | Fruzaqla, Ninlaro, Vonvendi |
| Genzyme Corporation | $434.85 | 2019-2025 | |
| Amgen INC. | $432.44 | 2019-2022 |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Eakle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.